Amniotic fluid derived mesenchymal stem cells reduce inflammation and improve lung function following transplantation in a porcine model
(2024) In The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation- Abstract
BACKGROUND: Lung transplantation is hindered by low donor lung utilization rates. Infectious complications are reasons to decline donor grafts due to fear of post-transplant primary graft dysfunction. Mesenchymal stem cells are a promising therapy currently investigated in treating lung injury. Full-term amniotic fluid-derived lung-specific mesenchymal stem cell treatment may regenerate damaged lungs. These cells have previously demonstrated inflammatory mediation in other respiratory diseases, and we hypothesized that treatment would improve donor lung quality and post-operative outcomes.
METHODS: In a transplantation model, donor pigs were stratified to either the treated or the non-treated group. Acute respiratory distress... (More)
BACKGROUND: Lung transplantation is hindered by low donor lung utilization rates. Infectious complications are reasons to decline donor grafts due to fear of post-transplant primary graft dysfunction. Mesenchymal stem cells are a promising therapy currently investigated in treating lung injury. Full-term amniotic fluid-derived lung-specific mesenchymal stem cell treatment may regenerate damaged lungs. These cells have previously demonstrated inflammatory mediation in other respiratory diseases, and we hypothesized that treatment would improve donor lung quality and post-operative outcomes.
METHODS: In a transplantation model, donor pigs were stratified to either the treated or the non-treated group. Acute respiratory distress syndrome was induced in donor pigs and harvested lungs were placed on ex vivo lung perfusion before transplantation. Treatment consisted of three doses of 2x10
6 cells/kg: one during ex vivo lung perfusion and two after transplantation. Donors and recipients were assessed on clinically relevant parameters and recipients were followed for 3 days before evaluation for primary graft dysfunction (PGD).
RESULTS: Repeated injection of the cell treatment showed reductions in inflammation seen through lowered immune cell counts, reduced histology signs of inflammation, and decreased cytokines in the plasma and bronchoalveolar lavage fluid. Treated recipients showed improved pulmonary function, including increased PaO
2/FiO
2 ratios and reduced incidence of PGD.
CONCLUSIONS: Repeated injection of lung-specific cell treatment during EVLP and post-transplant was associated with improved function of previously damaged lungs. Cell treatment may be considered as a potential therapy to increase the number of lungs available for transplantation and the improvement of post-operative outcomes.
(Less)
- author
- Edström, Dag LU ; Niroomand, Anna LU ; Stenlo, Martin LU ; Broberg, Ellen LU ; Hirdman, Gabriel LU ; Ghaidan, Haider LU ; Hyllén, Snejana LU ; Pierre, Leif LU ; Olm, Franziska LU and Lindstedt, Sandra LU
- organization
-
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Thoracic Surgery
- WCMM-Wallenberg Centre for Molecular Medicine
- Anesthesiology and Intensive Care
- Pediatric anesthesia and intensive care (research group)
- Clinical and experimental lung transplantation (research group)
- LUCC: Lund University Cancer Centre
- Cardiothoracic anesthesia and intensive care (research group)
- DCD transplantation of lungs (research group)
- Department of Clinical Sciences, Lund
- NPWT technology (research group)
- publishing date
- 2024-08-23
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
- publisher
- Elsevier
- external identifiers
-
- pmid:39182800
- ISSN
- 1557-3117
- DOI
- 10.1016/j.healun.2024.08.014
- language
- English
- LU publication?
- yes
- additional info
- Copyright © 2024. Published by Elsevier Inc.
- id
- 67a2ce90-dbd2-4cea-a546-327cf5f7c33d
- date added to LUP
- 2024-08-29 14:16:43
- date last changed
- 2024-08-29 15:45:32
@article{67a2ce90-dbd2-4cea-a546-327cf5f7c33d, abstract = {{<p>BACKGROUND: Lung transplantation is hindered by low donor lung utilization rates. Infectious complications are reasons to decline donor grafts due to fear of post-transplant primary graft dysfunction. Mesenchymal stem cells are a promising therapy currently investigated in treating lung injury. Full-term amniotic fluid-derived lung-specific mesenchymal stem cell treatment may regenerate damaged lungs. These cells have previously demonstrated inflammatory mediation in other respiratory diseases, and we hypothesized that treatment would improve donor lung quality and post-operative outcomes.</p><p>METHODS: In a transplantation model, donor pigs were stratified to either the treated or the non-treated group. Acute respiratory distress syndrome was induced in donor pigs and harvested lungs were placed on ex vivo lung perfusion before transplantation. Treatment consisted of three doses of 2x10<br> 6 cells/kg: one during ex vivo lung perfusion and two after transplantation. Donors and recipients were assessed on clinically relevant parameters and recipients were followed for 3 days before evaluation for primary graft dysfunction (PGD).<br> </p><p>RESULTS: Repeated injection of the cell treatment showed reductions in inflammation seen through lowered immune cell counts, reduced histology signs of inflammation, and decreased cytokines in the plasma and bronchoalveolar lavage fluid. Treated recipients showed improved pulmonary function, including increased PaO<br> 2/FiO<br> 2 ratios and reduced incidence of PGD.<br> </p><p>CONCLUSIONS: Repeated injection of lung-specific cell treatment during EVLP and post-transplant was associated with improved function of previously damaged lungs. Cell treatment may be considered as a potential therapy to increase the number of lungs available for transplantation and the improvement of post-operative outcomes.</p>}}, author = {{Edström, Dag and Niroomand, Anna and Stenlo, Martin and Broberg, Ellen and Hirdman, Gabriel and Ghaidan, Haider and Hyllén, Snejana and Pierre, Leif and Olm, Franziska and Lindstedt, Sandra}}, issn = {{1557-3117}}, language = {{eng}}, month = {{08}}, publisher = {{Elsevier}}, series = {{The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation}}, title = {{Amniotic fluid derived mesenchymal stem cells reduce inflammation and improve lung function following transplantation in a porcine model}}, url = {{http://dx.doi.org/10.1016/j.healun.2024.08.014}}, doi = {{10.1016/j.healun.2024.08.014}}, year = {{2024}}, }